Anna L. Godfrey - Concepedia

Author

Anna L. Godfrey

Also Known As

A Godfrey, A. Godfrey, A. L. Godfrey, A.L. Godfrey, Adriko Godfrey, Alex Godfrey, Andrew Godfrey, Anna Godfrey, Anna L Godfrey, Anna L. Godfrey

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

University of Cambridge Wellcome Sanger Institute Cambridge University Hospitals NHS Foundation Trust Wellcome/MRC Cambridge Stem Cell Institute Guy's and St Thomas' NHS Foundation Trust

About

Anna L. Godfrey is an author at University of Cambridge specializing in medicine, tumor biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	240
2	Cell Biology	2	2	113
3	Natural Sciences	1	1	54
4	Biology	1	1	54
5	Biostatistics	1	1	35

Anna L. Godfrey

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i> Jyoti Nangalia, Charles Massie, E. Joanna Baxter, New England Journal of Medicine	2013	1.7K
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts Elli Papaemmanuil, Mario Cazzola, Jacqueline Boultwood, New England Journal of Medicine	2011	1.2K
Classification and Personalized Prognosis in Myeloproliferative Neoplasms Jacob Grinfeld, Jyoti Nangalia, E. Joanna Baxter, New England Journal of Medicine	2018	586
Effect of Mutation Order on Myeloproliferative Neoplasms Christina A. Ortmann, David G. Kent, Jyoti Nangalia, New England Journal of Medicine	2015	559
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms Luca Malcovati, Elli Papaemmanuil, David Bowen, Blood	2011	493
Life histories of myeloproliferative neoplasms inferred from phylogenies. Nicholas Williams, Joe Lee, Emily Mitchell, Apollo (University of Cambridge)	2022	231
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms William Tapper, Amy V. Jones, Róbert Královics, Nature Communications	2015	160
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial Claire Harrison, Jyoti Nangalia, Rebecca H. Boucher, Journal of Clinical Oncology	2023	123
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone Anna L. Godfrey, Edwin Chen, Francesca Pagano, Blood	2012	102
Molecular diagnosis of the myeloproliferative neoplasms: <scp>UK</scp> guidelines for the detection of <i><scp>JAK</scp>2 </i><scp>V</scp>617<scp>F</scp> and other relevant mutations Anthony J. Bench, Helen White, Letizia Foroni, British Journal of Haematology	2012	92

Page 1